Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace Directory

Hsp70 ELISA kit, 5/14

May 2014—Enzo Life Sciences now offers the Amp’d HSP70 High Sensitivity ELISA Kit for detecting both baseline and upregulated levels of Hsp70 (Hsp72).

Insight Genetics and VICC partnership, 5/14

May 2014—Insight Genetics is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to identify genetic markers that will help select the targeted therapeutics most effective for each triple-negative breast cancer patient.

Data-management software upgrade, 5/14

May 2014—Siemens Healthcare released a software upgrade for the RAPIDComm Data Management System (V5.0), an informatics solution to centrally manage Siemens’ in vitro diagnostics analyzers and operators at the point of care. The upgrade includes the RAPIDComm Web Application, which allows POC coordinators to view the status of their POC instruments and troubleshoot from a handheld device.

FISH upgrades for improved virtual analysis, 5/14

May 2014—Clarient Diagnostic Service, a GE Healthcare company, upgraded its fluorescence in situ hybridization technologies to improve virtual analysis of test results for leukemia, lymphoma, myelodysplastic syndrome, and myeloma.

Reference standards, 5/14

May 2014—Cerilliant introduced 14 Snap-N-Spike solutions of phenethylamines, a class of drugs. These certified reference materials are suitable for numerous applications in GC/MS or LC-MS/MS testing, from urine drug monitoring and forensic testing to clinical toxicology analysis.

WaferGen acquisition, 5/14

May 2014—WaferGen Bio-systems acquired the NGS library preparation business from IntegenX. Pursuant to the purchase agreement, the company acquired substantially all of the assets of IntegenX’s product line used in connection with developing, manufacturing, marketing, and selling instruments and reagents relating to library preparation for NGS.

CLSI QMS15 guideline, 5/14

May 2014—The Clinical and Laboratory Standards Institute released a new quality management systems standard: QMS15-A—Laboratory Internal Audit Program; Approved Guideline. The document provides guidance on how a laboratory can establish an internal audit program to enhance the quality of its services through continual improvement. CLSI, 610-688-0100

Paper on IHC and prostate pathology, 5/14

May 2014—Dako released a paper titled “Immunohistochemistry in Prostate Pathology” that illustrates the significant impact immunohistochemistry can have on diagnostic prostate pathology.